TMEM97 and ovarian carcinoma: In a follow-upstudy, the structure of SW-43 was conjugated withthat of a second mitochondria-derived activator of caspase (SMAC)compound to develop an innovative class of tumor-targeting drug deliveryagents for treating ovarian cancer.146 Asa result, the new hybrid compound named SW III-123 (Figure 18) retained a sufficient σ2R affinity to allow the successful delivery of the SMAC compoundinto ovarian cancer cells.